Although these two chemotherapies were not standard treatment for DLBCL, patients in high-risk groups showed a significantly lower estimated IC50 and higher expression of CDK2 and BRAF, suggesting the potential value of Roscovitine and AZ628 as a rescue therapy. This evidence concerns the gene CDK2 and diffuse large B-cell lymphoma.